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Abstract
Objectives—Eosinophilic esophagitis (EoE) is difficult to distinguish from gastroesophageal 
reflux (GERD) and other causes of dysphagia. We assessed the utility of a set of clinical and 
endoscopic features for predicting EoE without obtaining esophageal biopsies.
Methods—We prospectively enrolled consecutive adults undergoing outpatient upper endoscopy 
at University of North Carolina from 7/2011–12/2013. Incident cases of EoE were diagnosed per 
consensus guidelines. Non-EoE controls had either GERD- or dysphagia-predominant symptoms. 
A predictive model containing clinical and endoscopic, but no histologic data was assessed. 
Receiver operator characteristic (ROC) curves were constructed and the area under the curve 
(AUC) was calculated.
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Results—A total of 81 EoE cases (mean age 38 years; 60% male; 93% white; 141 eos/hpf) and 
144 controls (mean age 52, 38% male; 82% white; 3 eos/hpf) were enrolled. A combination of 
clinical (age, sex, dysphagia, food allergy) and endoscopic (rings, furrows, plaques, hiatal hernia) 
features was highly predictive of EoE. The AUC was 0.944, with sensitivity, specificity, and 
accuracy of 84%, 97%, and 92%. Similar values were seen after limiting controls to those with 
only reflux or dysphagia, or to those with esophageal eosinophilia not due to EoE.
Conclusions—We validated a set of clinical and endoscopic features to predict EoE with a high 
degree of accuracy, and allow identification of those at very low risk of disease. Use of these 
predictors at the point-of-care will avoid the effort and expense of low-yield histological 
examinations for EoE.
Keywords
Eosinophilic esophagitis; gastroesophageal reflux disease; clinical prediction tool; validation; 
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Introduction
Eosinophilic esophagitis (EoE) is a clinicopathologic condition defined by symptoms of 
esophageal dysfunction and eosinophilic infiltration of the esophageal mucosa, in the 
absence of other causes (1–3). Despite this definition, distinguishing patients with EoE from 
patients with gastroesophageal reflux disease (GERD) symptoms remains clinically 
challenging. While dysphagia is the hallmark of EoE (1, 4, 5), many non-EoE conditions can 
cause dysphagia. Additionally, other symptoms in EoE patients including heartburn, reflux, 
and chest pain, can mimic GERD (6–8). Because of this substantial overlap (9, 10), it is not 
surprising that EoE has been found in 1% to 8% of patients with symptoms of GERD (11–
16). Moreover, an elevated eosinophil count on esophageal biopsy, the presumed hallmark 
of EoE, is not specific; high levels of esophageal eosinophils can be found in both diseases 
(9, 10, 15–22). The differentiation between EoE and GERD is critical, however, as 
evaluation, treatment, and prognosis for the two conditions are divergent. Improved 
techniques to separate these two entities are required.
We previously performed a study comparing clinical, endoscopic, and histologic features of 
EoE and GERD patients (23). While no individual feature was pathognomic, on 
multivariable analysis, a set of factors independently distinguished EoE from GERD, and 
had substantial utility for diagnosis of EoE as measured with receiver operator characteristic 
(ROC) curve analysis. However, this study was retrospective, encompassed a time frame 
when features of EoE might not have been universally recognized, did not assess patients 
with symptoms of dysphagia who did not have EoE, and included full histopathologic data 
in the model, which limited clinical utility.
The aim of the present study was to determine prospectively whether a set of clinical and 
endoscopic features could be used as a prediction tool to distinguish patients with EoE from 
patients with GERD- or dysphagia-predominant symptoms not caused by EoE without 
obtaining esophageal biopsies. We hypothesized that a multivariable model would 
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differentiate EoE cases from non-EoE controls with a high degree of accuracy as measured 
by the area under the receiver operating characteristic curve (AUC).
Methods
Study design and patient population
This was a prospective study performed at University of North Carolina from July, 2011 
through December, 2013. Consecutive adult patients (age 18–80 years) referred for 
outpatient esophagogastroduodenoscopy (EGD) were eligible for recruitment if they had 
symptoms of esophageal dysfunction, such as dysphagia, food impaction, heartburn, reflux, 
or chest pain, that could suggest EoE clinically. Subjects were excluded if they had a known 
(prevalent) diagnosis of EoE or a different eosinophilic gastrointestinal disorder (EGID), GI 
bleeding, active anticoagulation, known esophageal cancer, prior esophageal surgery, known 
esophageal varices, medical instability or multiple comorbidities precluding enrollment in 
the clinical opinion of the endoscopist, or inability to read or understand the consent form. 
Subjects provided informed consent and were enrolled prior to the endoscopy. Endoscopy 
could be performed by any of the gastroenterologists at UNC. A total of 15 attending 
physicians performed study endoscopies; the majority (73%) were performed by a single 
endoscopist (ESD). This study was approved by the UNC Institutional Review Board and 
registered on clinicaltrials.gov (NCT 01988285).
Case definitions and clinical data
EoE cases were diagnosed per consensus guidelines (1–3). They were required to have at 
least one typical symptom of esophageal dysfunction, an esophageal biopsy demonstrating 
≥15 eosinophils per high-power field (eos/hpf) after an 8 week trial of a proton-pump 
inhibitor (PPI; 20–40 mg twice daily of any of the available agents, prescribed at the 
discretion of the clinician), and other causes of esophageal eosinophilia excluded. 
Accordingly, baseline data for the EoE cases were obtained after the PPI trial and at the time 
of the confirmatory endoscopy, but prior to knowledge of the biopsy results and before any 
EoE-specific treatment was prescribed. Subjects who were enrolled and found to have 
esophageal eosinophilia but who were not on a PPI were prescribed a high-dose PPI trial. If 
symptoms and esophageal eosinophilia ≥ 15 eos/hpf persisted, EoE was diagnosed and they 
were included in the study. If symptoms and eosinophilia resolved (<15 eos/hpf), they were 
diagnosed with PPI-responsive esophageal eosinophilia (PPI-REE) and were not included in 
this analysis. PPI-REE was excluded for several reasons. First, because the major aim of the 
study was to predict EoE case status at endoscopy and prior to biopsy, we used the 
consensus diagnostic guidelines as the gold standard, and these guidelines require exclusion 
of PPI-REE. Second, previous work by us and others compared EoE and PPI-REE subjects, 
and found that clinical, endoscopic, and histologic features did not distinguish these groups 
(24–28). Finally, pH testing was not a component of this study, as it has not been shown to 
predict PPI-REE status or reflux as a cause of esophageal eosinophilia (25, 26, 29).
Non-EoE controls were subjects with symptoms of esophageal dysfunction as noted above 
who, after endoscopy and biopsy, did not meet clinical and histologic criteria for EoE. PPI 
use was not proscribed in this group and was at the discretion of the referring provider. 
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Controls with dysphagia-predominant and GERD-predominant symptoms (ie heartburn, 
reflux, chest pain) without consideration of clinical PPI response were recruited in equal 
numbers to allow for secondary analyses as noted below. This distinction was based on 
symptoms at the time of presentation for endoscopy, and represents a control group 
previously used for such studies, given that they are at risk for EoE and would otherwise 
meet disease definition if they had accompanying appropriate histological findings (30).
Standardized case report forms and a prospectively administered questionnaire were used to 
collect clinical data, including demographics, medical history, symptoms, allergic 
conditions, indications for endoscopy, endoscopic findings, and final diagnoses. Food 
allergies were provided by patient self-report, and could reflect either overt allergic reactions 
or sensitization. During endoscopy, esophageal biopsies for research use were obtained (two 
from the proximal, one from the mid, and two from the distal esophagus) to maximize EoE 
diagnostic sensitivity (31, 32). Gastric and duodenal biopsies were also collected for 
research purposes to exclude concomitant eosinophilic gastroenteritis. Additional clinical 
biopsies were taken as indicated at the discretion of the endoscopist.
The study pathologists quantified the esophageal eosinophil counts using our previously 
validated methodology (33). In brief, slides were masked to case/control status, digitized, 
and reviewed with Aperio ImageScope (Aperio Technologies, Vista, CA). Five microscopy 
fields from each of the five biopsies were examined to determine the maximum eosinophil 
density (eosinophils/mm2 [eos/mm2]). In order to compare results to prior studies, 
eosinophil density was converted to an eosinophil count (eos/hpf) using a hpf size of 0.24 
mm2, the most commonly reported field size in the literature (5). In addition to eosinophilic 
counts, associated histologic findings were also recorded. These included the presence of 
eosinophilic microabscesses (clusters of ≥ 4 eosinophils), eosinophil degranulation, basal 
layer hyperplasia (when evaluable in properly oriented specimens), spongiosis, and lamina 
propria fibrosis (if adequate subepithelial stroma was present (32, 34).
Statistical analysis
Distributions of all clinical, endoscopic, and histologic variables of interest were 
summarized and described. To compare the EoE cases and non-EoE controls, we used Chi-
square for categorical variables, and t-tests or Wilcoxon rank-sum test for continuous 
variables as appropriate for bivariate analysis.
Predictive models based on beta values derived from our previous study population of EoE 
cases and GERD controls (23) were generated and applied to the current prospectively 
recruited independent population. In brief, the prior study identified a number of factors on 
multivariate analysis that predicted EoE case status. The primary model of interest that we 
examined in the present study contained clinical and endoscopic, but no histologic data, so 
that EoE case status could be predicted without esophageal biopsy. Beta values and the 
associated ROC AUC data derived for this model from the dataset from the prior study are 
listed in Supplemental Table 1. Other models of secondary interest included: 1) a model 
with full clinical, endoscopic, and histologic data; 2) a model that did not contain the 
dysphagia and eosinophil count components of the EoE disease definition; and 3) a model 
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with only clinical, but no endoscopic or histologic, data. These beta values and AUC results 
from the prior dataset are listed in Supplemental Table 2.
These prior beta values were then used to construct a multivariate logistic regression model 
to predict EoE case status in the present study population. Diagnosis of EoE by the 
consensus guidelines was the gold standard. ROC curves were constructed and AUCs were 
calculated to determine the utility of the models. The AUCs were further contextualized by 
calculating the sensitivity, specificity, positive and negative predictive values (PPV; NPV), 
and accuracy. For the primary analysis, all non-EoE controls comprised a single group. 
Several a priori secondary analyses were also performed. The models were reanalyzed first 
limiting the non-EoE control group to those with dysphagia-predominant symptoms, and 
then to those with GERD-predominant symptoms. They were also reanalyzed limiting the 
control group to those subjects with an elevated eosinophil count at the ≥7 eos/hpf, and then 
also at the ≥10 eos/hpf levels. This allowed us to focus on the group of subjects for whom 
there would be the most diagnostic confusion. Finally, these analyses were also performed 
with the models of secondary interest.
The planned ROC analysis for the primary analysis determined the necessary sample size. 
By enrolling at least 60 EoE cases and 120 controls (half with dysphagia-predominant and 
half with GERD-predominant symptoms), we would have >80% power to detect a true AUC 
value of >0.90, a highly clinically relevant test performance level (35, 36). All analyses were 
performed with Stata version 9 (Statacorp, College Station, TX).
Results
Patient flow and characteristics
After screening 586 subjects referred for outpatient upper endoscopy, 276 were enrolled, 
yielding 81 EoE cases and 144 non-EoE controls (70 with dysphagia-predominant and 74 
with GERD-predominant symptoms); 51 patients with either PPI-REE or a clinically 
indeterminant phenotype were not analyzed for the purposes of this study (Figure 1).
There were clinical differences between the EoE and controls groups (Table 1). EoE cases 
were younger (38 vs 52 years; p < 0.001), more likely to be male (60% vs 38%; p = 0.001) 
and white (93% vs 82%; p = 0.03), and almost all had dysphagia (98%). Rates of atopy were 
high in both the EoE and control group (69% vs 58%; p = 0.09), though food allergies were 
more common in EoE (43% vs 15%; p < 0.001). Common diagnoses in the control group 
included GERD (47%), esophageal stricture or Schatzki’s ring (18%), functional disorders 
(17%), and esophageal dysmotility (13%). Additionally, while all of the EoE patients were 
on twice daily therapy at enrollment, 97 of controls (67%) were on PPI, of whom 58 (40%) 
were on twice daily dosing.
There were also multiple endoscopic and histologic differences between the two groups 
(Table 2). Very few (4%) of the endoscopic exams were normal in EoE cases. As would be 
expected in an EoE group, rings (78% vs 10%), furrows (86% vs 6%), and plaques (47% vs 
3%), were more common (p < 0.001 for all). In contrast, hiatal hernias were less common in 
the EoE group (14% vs 54%; p < 0.001). Stricture and dilation rates were comparable 
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between the two groups. On histology, the mean eosinophil counts for the cases and controls 
were 141 ± 119 eos/hpf and 3 ± 6 eos/hpf, respectively (p < 0.001). Associated histologic 
findings including eosinophil degranulation, microabscesses, basal zone hyperplasia, 
spongiosis, and lamina propria fibrosis were more common in the EoE cases.
Predictive modeling
For the primary predictive model analysis (clinical and endoscopic, but no histologic data, 
so that EoE case status could be predicted without esophageal biopsy), we used the beta 
values derived from an independent patient population in our prior study (Supplemental 
Table 1) (23). The variables included in this model were age, sex, dysphagia, food allergy, 
rings, furrows, plaques, and hiatal hernia. When these were applied to the prospectively 
enrolled patient population in the present study, the AUC of the predictive model was 0.944 
(Figure 2). The model correctly classified 92% of subjects, with a sensitivity of 84%, 
specificity of 97%, and PPV and NPV of 93% and 91%, respectively (Table 3). On sub-
analysis, the model performed similarly well. The AUC was 0.948 for the GERD-
predominant control sub-group, 0.940 for the dysphagia-predominant controls, 0.892 for 
controls with ≥10 eos/hpf, and 0.905 for controls with ≥7 eos/hpf. Similar results were also 
noted after stratifying the control group for baseline PPI status (for PPI users, AUC = 0.944; 
for non-PPI users, AUC = 0.965).
The analysis of the secondary models of interest also showed similar results. The beta values 
and variables used for these models are listed in Supplemental Table 2, and ROC curves are 
displayed in the Supplemental Figure. For the model with full clinical, endoscopic, and 
histologic data, the AUC was 0.981. For the model that did not contain the dysphagia and 
eosinophil count components of the EoE disease definition, the AUC was 0.973. For the 
model with only clinical, but no endoscopic or histologic, data, the AUC was not as good at 
0.862. Even though dysphagia was a strong factor in all of the models, there was a clinically 
and statistically significant gain in the predictive power as measured by the AUC between 
the model of clinical factors alone and our primary model of clinical and endoscopic factors 
(p<0.01). This is reflected by an increase in the proportion of EoE cases correctly classified 
from 76% to 92%.
Discussion
Despite publication of consensus diagnostic criteria for EoE (1–3), there are no pathognomic 
symptoms or signs of the disease, and therefore EoE remains challenging to distinguish from 
other causes of esophageal eosinophilia, particularly GERD, both before and after 
esophageal biopsy (5, 10, 16, 18, 23). Our previous work identified a set of clinical, 
endoscopic, and histologic features, that, when taken together, were highly predictive of 
EoE case status (23). However, the methodology of that study was limited by its 
retrospective nature and requirement for full biopsy information.
The present prospective study aimed to validate a set of clinical and endoscopic features that 
could distinguish EoE from non-EoE controls with symptoms of esophageal dysfunction, 
including symptoms of dysphagia and GERD, without esophageal biopsy by using 
previously derived beta values and applying them to a newly recruited independent 
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population. We found that eight easily obtainable measures, including younger age, male 
sex, presence of dysphagia and food allergies, presence of esophageal rings, furrows, and 
plaques, and lack a hiatal hernia, predicted EoE diagnosis with a very high degree of 
accuracy. The results held on additional analyses examining dysphagia-predominant and 
GERD-predominant controls, and in controls with elevated eosinophil counts not due to 
EoE. Moreover, we also validated a highly accurate model that could be used when full 
histologic data are available. Taken together, these models have a high degree of clinical 
utility, both to minimize the need for biopsy in low-yield patients, and to help distinguish 
EoE from other clinical conditions when there is a diagnostic conundrum.
There has been intense interest in methods to distinguish EoE from GERD, including 
analysis of tissue biomarkers (20, 22, 37–43), non-invasive biomarkers (44–47), and most 
recently, genetic expression profiling (48). While there have also been recent efforts to 
validate symptom and quality of life measures (49–53), the goal of these investigations has 
not been to use the symptom scores to diagnose EoE per se. There have been only a few 
prior attempts to generate clinical prediction tools to identify EoE cases. Aceves and 
colleagues studied 35 children with EoE and 27 with GERD, and found that the presentation 
between the groups was similar, but that dysphagia and anorexia/early satiety were more 
common in EoE and correlated with endoscopic and histologic findings (54). von Arnim and 
colleagues analyzed clinical and laboratory features of 23 adults with EoE and 20 with 
GERD, and after logistic regression found that three factors – peripheral eosinophilia, 
history of food impaction, and PPI-refractory heartburn symptoms – were predictive of EoE 
with sensitivity of 91% and specificity of 100% (55). Mulder and colleagues identified 163 
adult and pediatric EoE cases, and an equal number of GERD controls (56). Using 
methodology similar to our prior study (23), they generated a predictive model containing 
six characteristics – sex, dysphagia, chest pain/heartburn, food impaction, furrows, and 
plaques – which was able to distinguish EoE from GERD with an AUC of 0.858. With the 
exception of the study by Aceves, the others have been retrospective, and none have 
attempted to validate the findings in an independent population.
In this study, we present a clinically relevant predictive model. Being able to recognize 
patients with symptoms of esophageal dysfunction who are most likely to have EoE, as well 
as those in whom there is a very low likelihood of EoE, based on clinical and endoscopic 
factors alone, allows a clinical decision to be made as to whether to obtain an esophageal 
biopsy. Several prospective studies have shown that esophageal eosinophilia or EoE will be 
found in up to 3–7% of patients undergoing endoscopy for any reason (57, 58), in up to 23% 
undergoing endoscopy for dysphagia (24, 59–61), and in 1–8% undergoing endoscopy for 
PPI-refractory heartburn symptoms (11–14, 62). Because of this, current guidelines 
recommend obtaining esophageal biopsies in all patients with dysphagia to assess for EoE, 
as well considering biopsy in patients with PPI-refractory GERD (2, 3, 63). In such a 
paradigm, there will be far more negative than positive biopsies, particularly in patients with 
GERD-predominant symptoms. In one analysis, the prevalence of EoE in heartburn patients 
had to be at least 8%, the top of the reported range, for biopsy to be cost-effective (64). 
Moreover, a recent study of shows EoE health care-related costs are approaching $1 billion 
annually, a remarkable amount for a relatively uncommon disease (65). Therefore, it is 
imperative to minimize costs when the biopsy yield is low. Our study provides a model that 
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can do just that. Because of the very high specificity and NPV, it can accurately identify 
patients unlikely to have EoE, and therefore not require esophageal biopsy. To aid in this 
process, we have created an on-line calculator that can be used at the point-of-care to 
provide the probability of an EoE diagnosis (https://gicenter.med.unc.edu/cedas/
eoe_clinical_calculator.html).
This study does have limitations. We did not use validated measures to characterize severity 
of symptoms or endoscopic findings. While those measures are now available (49, 50, 66), 
they did not exist when this study was designed. With the modeling strategy that we 
employed, only the presence or absence of symptoms and endoscopic signs was required, a 
metric that is easy to use clinically. Given the excellent performance characteristics of the 
model, it is unlikely that more complicated assessment of symptom severity would have 
markedly improved its performance. Second, we did not analyze patients with PPI-REE. The 
overall aim of this study was to distinguish EoE from GERD and other esophageal 
conditions, and we and others have previously shown that clinical and endoscopic 
characteristics do not distinguish EoE from PPI-REE (24–28), so we did not repeat that 
analysis here. We would emphasize, however, that these predictive models are most 
appropriately used for patients after a PPI trial. Related to this, two-thirds of controls were 
on PPI. While there was no way to know whether a patient with GERD symptoms on PPI 
who had an endoscopy and normal biopsies had prior esophageal eosinophilia, we suspect 
that this type of misclassification would be rare, and if present would have biased the results 
towards the null. Third, this was an adult population, so we cannot comment on whether the 
same factors would have utility in a pediatric population. However, because we have 
provided the beta values from our results, it would be possible to assess the utility of this 
model in an independent pediatric population. Finally, we did not perform standardized food 
allergy testing in this patient population. The food allergy variable in the model relies on 
patient self-report, and could include either overt food allergies or food sensitizations. 
However, our dichotomous patient self-report mimics clinical practice by allowing a 
practitioner to fill in the needed data for the model after asking a simple yes/no question.
This study also has a number of strengths. It is the largest prospective study to assess a 
clinical predictive tool for EoE. It applied beta values developed from a prior study 
population to validate the results in the present independent subject group. The screening 
and enrollment strategy was comprehensive and focused on a clinically relevant population, 
patients undergoing endoscopy for symptoms of esophageal dysfunction, from which the 
majority of EoE cases come, and in whom the vast majority of difficulty in making an EoE 
diagnosis occurs. While there might be some referral bias for patients seen in an outpatient 
endoscopy unit at a tertiary care institution, the broad inclusion criteria, the use of the 
consensus guidelines for diagnosis of EoE, and the variety of underlying causes of 
symptoms in the control group, should make the results relatively generalizable. Therefore, 
we feel that the resultant model has substantial clinical utility. It distinguishes EoE from 
non-EoE controls with a high degree of accuracy, and the operating characteristics of the 
model impact a relevant clinical decision, whether or not to obtain esophageal biopsies. 
Given that high costs from endoscopy and biopsy constitute a substantial portion of the 
overall costs of EoE patients (65), the question of whether to biopsy has special relevance in 
this population. Moreover, we performed several pre-specified sub-analyses that show that 
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the model performs equally well in patients with dysphagia-predominant or GERD-
predominant symptoms, as well as the subset of control patients who have elevated 
esophageal eosinophil counts. Finally, we also analyzed several secondary models, and 
when full clinical, endoscopic, and histologic data are available, these models also perform 
very well.
In conclusion, we have performed a prospective study that validated a set of clinical and 
endoscopic features, including younger age, male sex, presence of dysphagia and food 
allergy, presence of esophageal rings, furrows, and plaques, and lack of hiatal hernia, 
predicts EoE with a high degree of accuracy. Using these predictors at the point-of-care to 
aid with clinical decision making (https://gicenter.med.unc.edu/cedas/
eoe_clinical_calculator.html) will avoid the effort and expense of low-yield histological 
examination for EoE, and also provide guidance in cases where differentiating EoE from 
other conditions is challenging.
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What is current knowledge?
• Differentiating eosinophilic esophagitis (EoE) from gastroesophageal reflux 
disease (GERD) and other causes of dysphagia remains clinically challenging, 
but the distinction is critical, as evaluation, treatment, and prognosis for the two 
conditions are divergent.
• There are currently no prospectively validated models to predict EoE case status 
to use in routine clinical practice.
What is new here?
• We performed a prospective study of adults undergoing outpatient upper 
endoscopy, identified EoE cases and non-EoE controls, and assessed a 
predictive model containing clinical and endoscopic, but no histologic data.
• A set of clinical (younger age, male sex, dysphagia, food allergy) and 
endoscopic (rings, furrows, plaques, and lack of hiatal hernia) features were 
highly predictive of EoE. The AUC was 0.944, with sensitivity, specificity, and 
accuracy of 84%, 97%, and 92%.
• These operating characteristics held in the subset of controls with esophageal 
eosinophilia, as well as for models incorporating all clinical, endoscopic, and 
histologic features.
• This validated combination of clinical and endoscopic predictors can be used at 
the point-of-care to aid with clinical decision making.
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Patient flow and enrollment in this study. Of the 261 who were ineligible, 61 had non-
esophageal symptoms (ie abdominal pain, diarrhea, weight loss, etc), 23 had anemia or GI 
bleed, 24 had a malignancy, 36 had prior upper GI surgery, 9 had known esophageal 
dysmotility, 51 had known causes of their symptoms and were undergoing therapeutic 
endoscopy (ie prior esophageal stricture; treatment of Barrett’s esophagus, etc), and 57 had 
medical contraindications (varices, coagulopathy, multiple medical comorbidities, etc). Of 
the 15 who were not classified, 4 had prevalent EoE, 2 had a new diagnosis of eosinophilic 
gastroenteritis, 2 had a new diagnosis of esophageal cancer, and 7 did not complete a PPI 
trial to complete the EoE diagnostic algorithm during the study time frame.
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Receiver operating characteristic (ROC) curve for predicting EoE case status prior to 
esophageal biopsy using consensus guidelines as the gold standard. The dotted gray line 
represents a test that performs no better than chance, which by definition has an area under 
the curve (AUC) of 0.5. For this figure, the primary model of interest with clinical and 
endoscopic, but no histologic features, was used.
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Table 1







Age at diagnosis (mean ± SD) 51.6 ± 13.5 38.1 ± 13.3 < 0.001
Male (n, %) 54 (38) 49 (60) 0.001
White (n, %) 118 (82) 75 (93) 0.03
Symptoms/EGD indication (n, %)
  Dysphagia 108 (75) 79 (98) < 0.001
  Heartburn 103 (72) 14 (17) < 0.001
  Abdominal pain 9 (6) 7 (8) 0.50
  Nausea/vomiting 12 (8) 2 (2) 0.08
Atopic disorders (n, %)
  Asthma 33 (23) 22 (27) 0.48
  Atopic dermatitis 10 (7) 5 (6) 0.82
  Allergic rhinitis/sinusitis 69 (48) 50 (62) 0.05
  Food allergies 21 (15) 35 (43) < 0.001
  Any atopic disease 83 (58) 56 (69) 0.09
Final diagnoses (n, %)
  GERD 67 (47) - -
    Erosive 17 (12) - -
    Non-erosive 45 (31) - -
    BE 5 (3) - -
  Stricture - -
    Peptic 12 (8) - -
    Radiation 2 (1) - -
    Other 4 (3) - -
  Schatzki’s ring 9 (6) - -
  Anti-reflux surgery site defect 3 (2) - -
  Esophageal dysmotility - -
    Achalasia 3 (2) - -
    Spasm 7 (5) - -
    Other 9 (6) - -
  Zenker’s diverticulum 1 (1) - -
  Functional 25 (17) - -
  Candidal esophagitis 2 (1) - -
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Table 2







EGD findings at baseline (n, %)
  Normal 23 (16) 3 (4) 0.006
  Rings 14 (10) 63 (78) < 0.001
  Stricture 26 (18) 20 (25) 0.24
  Narrowing 5 (3) 25 (31) < 0.001
  Furrows 9 (6) 70 (86) < 0.001
  Crêpe-paper 3 (2) 6 (7) 0.05
  White plaques/exudates 4 (3) 38 (47) < 0.001
  Decreased vascularity 5 (3) 47 (58) < 0.001
  Erosive esophagitis 22 (15) 2 (2) 0.003
  Schatzki’s ring 16 (11) 9 (11) 1.0
  Hiatal hernia 78 (54) 11 (14) < 0.001
  Dilation performed 44 (31) 28 (35) 0.54
Baseline max eosinophil count (mean eos/hpf ± SD) 2.5 ± 6.3 140.5 ± 119.0 < 0.001
  Median eosinophil count (IQR) 0 (0–2) 113 (58–166) < 0.001
Baseline histology findings (n, %)*
  Eosinophil degranulation 17 (13) 71 (95) < 0.001
  Eosinophil microabscess 3 (2) 52 (69) < 0.001
  Basal zone hyperplasia 16 (13) 33 (45) < 0.001
  Spongiosis 53 (41) 68 (91) < 0.001
  Sub-epithelial stroma present 35 (27) 46 (61) < 0.001
  Lamina propria fibrosis 4 (11) 16 (35) 0.02
*
data available for 203 subjects
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Table 3
Diagnostic operating characteristics for the primary predictive model analysis










  Reflux controls (n = 74) 0.948
  Dysphagia controls (n = 70) 0.940
  Controls with ≥ 10 eos/hpf (n = 11) 0.892
  Controls with ≥ 7 eos/hpf (n = 15) 0.905
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